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Neutrophil elastase mutations and risk of leukaemia in severe
congenital neutropenia
Severe congenital neutropenia (SCN) is an inherited bone
marrow failure syndrome that is usually diagnosed in very
young children on the basis of absolute neutrophil count
(ANC) values persistently below 0Æ50 · 109/l, with maturation
arrest of neutrophil precursors in the bone marrow (Ancliff,
2003). Maintenance therapy with granulocyte colony-stimu-
lating factor (G-CSF) is standard of care to prevent the
occurrence of life-threatening bacterial sepsis (Dale et al,
1993). SCN is considered to be a pre-leukaemic disorder,
and the cumulative incidence of myelodysplastic syndrome
and acute myeloid leukaemia (MDS/AML) is extraordinarily
high (Rosenberg et al, 2006).
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Summary
Severe congenital neutropenia (SCN) is a heterogeneous bone marrow failure
syndrome predisposing to myelodysplastic syndrome and acute myeloid
leukaemia (MDS/AML). We studied 82 North American and Australian SCN
patients enrolled in the Severe Chronic Neutropenia International Registry
who were on long-term treatment with granulocyte colony-stimulating factor
and for whom the neutrophil elastase (ELA2) gene was sequenced. There was
no significant difference in the risk of MDS/AML in patients with mutant
versus wild-type ELA2: the respective cumulative incidences at 15 years were
36% and 25% (P = 0Æ96). Patients with either mutant or wild-type ELA2
should be followed closely for leukaemic transformation.
Keywords: severe congenital neutropenia, neutrophil elastase ELA2, acute
myeloid leukaemia, myelodysplastic syndromes, granulocyte colony-stimu-
lating factor.
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Severe congenital neutropenia is genetically heterogeneous.
A majority of cases are attributed to autosomal dominant
mutations (inherited or sporadic) in the gene encoding
neutrophil elastase (ELA2) (Dale et al, 2000). Other rare
causative genes have recently been found, including mutations
in HAX1 (Klein et al, 2007), but the prevalence of mutations in
these genes in the general SCN population has yet to be
determined (Boxer & Newburger, 2007).
Following the identification of disease-associated genes, an
emerging clinical concern is to identify genotype-phenotype
associations that might inform therapeutic decisions. The
largest published studies addressing this question have pre-
sented clinical data for a total of 23 (Ancliff et al, 2003) and 54
(Bellanne-Chantelot et al, 2004) SCN patients stratified
according to the presence or absence of any mutation in
ELA2. This report describes associations of ELA2 mutation
status with responsiveness to G-CSF therapy and risk of MDS/
AML in a larger cohort of 82 North American and Australian
patients on long-term G-CSF, prospectively followed in the
Severe Chronic Neutropenia International Registry (SCNIR)
(Dale et al, 2003).
Patients, materials and methods
The Severe Chronic Neutropenia International Registry
We studied patients enrolled in the SCNIR who had been
diagnosed with SCN by their treating haematologist and who
had blood or fibroblast samples stored in the University of
Washington repository serving SCNIR patients from North
America or Australia. Each patient specifically had a diagnosis
of SCN; those with a diagnosis of cyclic neutropenia,
Shwachman-Diamond Syndrome, or other related disorder
were excluded. The 82 SCN patients included here (from 104
with any available samples) were all those with sufficient DNA
for ELA2 sequencing, irrespective of baseline ANC or clinical
response to G-CSF. ELA2 mutation analysis was conducted
using standard polymerase chain reaction methods, Big Dye
terminator technology, and an ABI analyzer (Applied Biosys-
tems, Foster City, CA, USA). Validated data on G-CSF dose,
and results of complete blood cell counts, were extracted from
the database created for a prior study (Rosenberg et al, 2006).
Follow-up for occurrence of MDS/AML, bone marrow
transplant (BMT), or death from bacterial sepsis or other causes
was current up to October 12, 2006 for all patients. This study
was conducted in accordance with the Declaration of Helsinki,
under the auspices of the Human Subjects Committee of the
University of Washington and other participating institutions.
Patients provided informed consent for genetic studies. All
statistical analyses were performed on anonymized samples.
Statistical methods
We used a generalized linear model for dose–response analysis.
For analysis of leukaemia risk, BMT or death from sepsis or
other causes were considered to be censoring events. We tested
for differences in rates using an exact binomial test, and
differences in cumulative incidence using Cox models and
likelihood ratio tests. All statistical tests were two-sided.
P < 0Æ05 was significant.
Results
The 82 patients were all treated with G-CSF. Treatment was
initiated between 1987 and 2000 at a median age of 24 months.
Subsequently, the patients contributed 904 person-years of
follow-up, during which time 20 transformed to MDS/AML.
Median follow-up was 10 years, ranging from 0Æ7 to 18Æ4 years.
Fifty-two patients had ELA2 mutations (63%), and 30
patients had wild-type ELA2 (37%). A total of seven, five, four
and three patients carried the Pro110Leu, Ser97Leu,
Gly185Arg, Val72Met missense mutations respectively. The
33 remaining patients harboured 27 other mutations.
Patients with mutant ELA2 had 2Æ8-fold [95% confidence
interval (CI): 1Æ4–5Æ5-fold] higher mean ANC than patients
with wild-type ELA2, after controlling for G-CSF dose. In
patients with mutant ELA2, the mean ANC on treatment was
close to or above the therapeutic target of 1Æ5 · 109 cells/l at
every dose level (Fig 1). In contrast, patients with wild-type
ELA2 reached the therapeutic target only if they responded to
comparatively low doses of G-CSF.
Fig 1. Granulocyte colony-stimulating factor (G-CSF) dose and
absolute neutrophil count (ANC) response in patients with SCN, by
ELA2 mutation status. Average ANC on therapy during the
6–18 month follow-up period on G-CSF, for patients with wild-type
(blue) and mutant (black) ELA2, according to G-CSF dose (lg/kg/d) at
6 months. Dose was analysed on the log2 scale and ANC on the log10
scale. Solid lines show mean values from a generalized linear model
that allows for a different linear relationship in patients with mutant
versus wild-type ELA2. Shaded areas correspond to 95% point-wise
confidence limits. Reference line at 1Æ5 · 109 cells/l shows the thera-
peutic target ANC. Median G-CSF dose was 5Æ2 lg/kg/d in patients
with wild-type ELA2 and 9Æ9 lg/kg/d in patients with mutant ELA2.
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Among 52 patients with mutant ELA2, 14 (27%) eventually
developed MDS/AML, compared with six (20%) of 30 patients
with wild-type ELA2; the crude proportions transforming to
MDS/AML were not significantly different (P = 0Æ67). Con-
trolling for years-on-G-CSF, there was no significant difference
in the cumulative incidence of MDS/AML in patients with
mutant versus wild-type ELA2 (P = 0Æ96): the cumulative
incidences at 15 years were 36% (mutant) and 25% (wild-
type), with broad and overlapping confidence intervals (Fig 2).
In all patients combined, the cumulative incidence was 34%
(95% CI: 19–46%) at 15 years.
We considered the effects of specific ELA2 mutations among
the 52 patients with any mutation. Two preliminary findings
emerged in exploratory analysis. First, the four patients with
Gly185Arg had a particularly severe course. On treatment,
ANC values were low despite high doses of G-CSF, and two
patients maintained on comparatively high doses of 48 and
21 lg/kg/d G-CSF developed MDS/AML at 10Æ1 and
15Æ1 years. Second, no MDS/AML events were observed in
seven patients with the Pro110Leu missense mutation or in five
patients with the Ser97Leu missense mutation. The crude rate
of MDS/AML was significantly lower in these 12 patients than
in the 40 with any other ELA2 mutation (0 events in 153
person-years versus 14 events in 468 person-years, respectively,
P = 0Æ04).
Discussion
Our study is the largest to date of ELA2 mutations and clinical
outcomes in SCN. It is well known that almost all SCN patients
respond to G-CSF, but there is considerable heterogeneity in
the dose of G-CSF required to obtain a haematological
response. In this study, we observed that patients with mutant
ELA2 usually responded with higher ANC values at lower doses
of G-CSF than patients with wild-type ELA2. As an exception
to this general trend, we observed a particularly severe course
in the four patients in our study with the ELA2 mutation
Gly185Arg, consistent with the report from the French
Neutropenia Registry that also had four SCN patients with
this mutation (Bellanne-Chantelot et al, 2004).
Notwithstanding these differences in response to therapy, an
important finding was that patients with or without mutations
in ELA2 were at extraordinary risk of MDS/AML. Indeed, there
was no significant difference in risk between the two groups. In
all patients combined, the cumulative incidence of MDS/AML
was 34% after 15 years on G-CSF.
We do not believe that selection or referral bias had a major
impact on our analysis. Considering patients who enroled
during the same calendar periods, we found no differences in
the rates of loss-to-follow-up according to ELA2 mutation
status (data not shown). Furthermore, the incidence of MDS/
AML was similar in the patients included here, compared to
other SCN patients in the SCNIR who were not included.
Together, these observations suggest that our analyses of MDS/
AML are statistically valid.
In contrast to our results, the French Neutropenia Registry
reported a significantly reduced leukaemia risk in patients with
wild-type ELA2, based on their observation that no patient
with wild-type transformed (Bellanne-Chantelot et al, 2004).
Our study was larger, with 20 MDS/AML events versus three
MDS/AML events, and one acute lymphoblastic leukaemia
event in the French study. We attribute the divergent results to
statistical heterogeneity, and possibly, genetic heterogeneity
between ELA2 wild-type patients in the respective studies. Our
results suggest that it is the marrow disorder that leads to
leukaemia, not simply the presence of an ELA2 mutation, and
leads to the prediction that patients with wild-type ELA2 who
develop leukaemia may ultimately be found to harbour
mutations in a number of other causative genes.
Although the average incidence of MDS/AML in our cohort
was similar in patients with and without ELA2 mutations,
exploratory analysis supports the concept that susceptibility to
MDS/AML varies by mutation. The subgroup of SCN patients
with the Gly185Arg missense mutation may be at increased
risk, given our findings and the leukaemias in this group
reported by the French Neutropenia Registry (Bellanne-
Chantelot et al, 2004). In addition, in our data, SCN patients
with the Pro110Leu or Ser97Leu missense mutations were at
significantly decreased risk. Interestingly, these specific ELA2
mutations are among the limited number associated with both
SCN and cyclic neutropenia (Horwitz et al, 2007).
From the clinical perspective, SCN patients with a wide
diversity of ELA2 mutations, and SCN patients without ELA2
mutations, have been observed to transform to leukaemia.
Therefore, the average risk is extraordinarily high. Until more
refined predictions are available, all SCN patients should be
considered at high risk. Our data also suggest that patients
Fig 2. Cumulative incidence of MDS/AML in patients with SCN, by
ELA2 mutation status. Cumulative incidence, by years on G-CSF
therapy, and 95% confidence intervals at selected years (error bars), in
patients with mutant (black) and wild-type (blue) ELA2. The Kaplan–
Meier actuarial method was used to estimate the cumulative incidence
curves.
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with wild-type ELA2 who do not respond to standard doses of
G-CSF are comparatively unlikely to respond to high doses.
These patients should be considered for early haematopoietic
stem cell transplantation, because they may be at high risk of
mortality from sepsis. It is now essential to develop new
practice guidelines for SCN (Touw & Bontenbal, 2007). These
guidelines will need to carefully weigh the potential risks and
benefits of G-CSF therapy versus transplantation, and specify
the appropriate role and timing of genetic and molecular tests
in counselling and decision-making.
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